Page last updated: 2024-11-04

risedronic acid and Cancer of Prostate

risedronic acid has been researched along with Cancer of Prostate in 13 studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Research Excerpts

Excerpt	Relevance	Reference
"Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss."	2.76	Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. ( Izumi, K; Kitagawa, Y; Koh, E; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K, 2011)
"Androgen-deprivation therapy for prostate cancer decreases bone mineral density and increases the risk of fracture."	2.73	Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. ( Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K, 2007)
"Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1."	2.66	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020)
"Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases."	2.41	Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)
"Breast or prostate cancer patients were treated with zoledronate."	1.39	Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013)
"A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone naïve)."	1.35	[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. ( Bab, S; Hayakawa, K; Hyodo, T; Iwamura, M; Kimura, M; Matsumoto, K; Okazaki, M; Satoh, T; Soh, S; Tabata, K; Tsuboi, T; Yokoyama, E, 2008)

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (38.46)	29.6817
2010's	6 (46.15)	24.3611
2020's	2 (15.38)	2.80

Authors

Authors	Studies
Jakob, T	1
Tesfamariam, YM	1
Macherey, S	1
Kuhr, K	1
Adams, A	1
Monsef, I	1
Heidenreich, A	1
Skoetz, N	1
Tripto-Shkolnik, L	1
Rouach, V	1
Nomura, T	1
Shibahara, T	1
Uchiyama, T	1
Yamamoto, N	1
Shibui, T	1
Yakushiji, T	1
Watanabe, A	1
Muramatsu, K	1
Ogane, S	1
Murayama, M	1
Sekine, R	1
Nakata, E	1
Fujimoto, Y	1
Izumi, K	2
Mizokami, A	2
Sugimoto, K	2
Narimoto, K	2
Miwa, S	1
Maeda, Y	1
Kadono, Y	1
Takashima, M	1
Koh, E	2
Namiki, M	2
Kearns, AE	1
Northfelt, DW	1
Dueck, AC	1
Atherton, PJ	1
Dakhil, SR	1
Rowland, KM	1
Fuloria, J	1
Flynn, PJ	1
Dentchev, T	1
Loprinzi, CL	1
Taxel, P	1
Dowsett, R	1
Richter, L	1
Fall, P	1
Klepinger, A	1
Albertsen, P	1
Kitagawa, Y	1
Meulenbeld, HJ	1
van Werkhoven, ED	1
Coenen, JL	1
Creemers, GJ	1
Loosveld, OJ	1
de Jong, PC	1
Ten Tije, AJ	1
Fosså, SD	1
Polee, M	1
Gerritsen, W	1
Dalesio, O	1
de Wit, R	1
Choo, R	1
Lukka, H	1
Cheung, P	1
Corbett, T	1
Briones-Urbina, R	1
Vieth, R	1
Ehrlich, L	1
Kiss, A	1
Danjoux, C	1
Hershman, D	1
Narayanan, R	1
Ishizaka, K	1
Machida, T	1
Kobayashi, S	1
Kanbe, N	1
Kitahara, S	1
Yoshida, K	1
Kimura, M	1
Satoh, T	1
Okazaki, M	1
Tabata, K	1
Tsuboi, T	1
Hyodo, T	1
Yokoyama, E	1
Matsumoto, K	1
Soh, S	1
Iwamura, M	1
Hayakawa, K	1
Bab, S	1
Major, PP	1
Lipton, A	1
Berenson, J	1
Hortobagyi, G	1

Clinical Trials (11)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695]	Phase 2	0 participants	Interventional	1999-03-31	Terminated
Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558]	Phase 2	44 participants	Interventional	2001-12-31	Completed
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001]	Phase 3	645 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650]	Phase 2	111 participants (Actual)	Interventional	2005-01-31	Completed
Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232]	Phase 3	227 participants (Actual)	Interventional	1997-11-24	Completed
A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646]	Phase 3	227 participants (Actual)	Interventional	2008-05-31	Completed
A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918]	Phase 2	300 participants (Anticipated)	Interventional	2005-02-28	Completed
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620]	Phase 3	1,904 participants (Actual)	Interventional	2006-04-01	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060]	Phase 3	63 participants (Actual)	Interventional	2003-10-31	Terminated (stopped due to Terminated due to low accrual)
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476]	Phase 2/Phase 3	11,992 participants (Actual)	Interventional	2005-07-08	Active, not recruiting
Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study[NCT00043069]	Phase 3	71 participants (Actual)	Interventional	2002-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival

Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	37.9
Placebo + Androgen Deprivation Therapy	36.0

Progression-free Survival

"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	10.6
Placebo + Androgen Deprivation Therapy	9.2

Time to First Skeletal Related Event

Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years

Intervention	months (Median)
Zoledronic Acid + Androgen Deprivation Therapy	31.9
Placebo + Androgen Deprivation Therapy	28.8

Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol

Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	25
Denosumab 180 mg Q12W	32
Denosumab 180 mg Q4W	35

Hypercalcemia

Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	0
Denosumab 180 mg Q12W	0
Denosumab 180 mg Q4W	0

Percent Change of Serum CTX From Baseline to Week 25

Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25

Intervention	Percent change (Mean)
Bisphosphonate IV Q4W	-40.68
Denosumab 180 mg Q12W	-76.74
Denosumab 180 mg Q4W	-68.39

Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25

Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25

Intervention	Percent change (Mean)
Bisphosphonate IV Q4W	-32.91
Denosumab 180 mg Q12W	-69.09
Denosumab 180 mg Q4W	-41.68

Skeletal Related Events

Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	6
Denosumab 180 mg Q12W	4
Denosumab 180 mg Q4W	2

Time to First Skeletal Related Event

Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25

Intervention	Participants (Number)
Bisphosphonate IV Q4W	6
Denosumab 180 mg Q12W	4
Denosumab 180 mg Q4W	2

Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol

Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25

Intervention	Days (Median)
Bisphosphonate IV Q4W	65
Denosumab 180 mg Q12W	9
Denosumab 180 mg Q4W	10

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13

Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks

Intervention	Participants (Number)
Bisphosphonate IV Q4W	10
Denosumab 180 mg Q12W	21
Denosumab 180 mg Q4W	28

uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25

Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks

Intervention	Participants (Number)
Bisphosphonate IV Q4W	13
Denosumab 180 mg Q12W	21
Denosumab 180 mg Q4W	23

Time to the First On-Study SRE (Non-inferiority)

Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months

Intervention	Days (Median)
Zoledronic Acid	521.0
Denosumab	629.0

Time to the First On-Study SRE (Superiority)

Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months

Intervention	Days (Median)
Zoledronic Acid	521.0
Denosumab	629.0

Time to the First-And-Subsequent On-Study SRE

"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months

Intervention	Events (Number)
Zoledronic Acid	584
Denosumab	494

Numbers of SRE or Death Occurred Cumulatively

Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months

Intervention	participants (Number)
Risedronate Arm	11
Placebo Arm	13

Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL

(NCT00216060)
Timeframe: 36 months

Intervention	percentage of participants (Number)
Risedronate Arm	50
Placebo Arm	29

Three- Year Survival Rate

(NCT00216060)
Timeframe: 36 months

Intervention	percentage of participants (Number)
Risedronate	72.5
Placebo	71.5

Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)

"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks

Intervention	nmol/mmol creatinine (Median)
	week 24	baseline
Placebo Arm	12.62	10.12
Risedronate Arm	6.91	8.83

Bone Turnover Marker Changes-- Serum BAP

Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week

Intervention	ng/mL (Median)
	24 week	baseline
Placebo Arm	13.16	19.50
Risedronate Arm	9.5	20.95

Bone Turnover Marker Changes-- Serum Osteocalcin (OC)

Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week

Intervention	ug/L (Median)
	at 24 week	baseline
Placebo Arm	27.35	18.24
Risedronate Arm	11.88	20.08

Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median

"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week

Intervention	nmol BCE/mmol creatinine (Median)
	at 24 week	baseline
Placebo Arm	62.95	48.08
Risedronate Arm	20.63	41.33

Reviews

3 reviews available for risedronic acid and Cancer of Prostate

Article	Year
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the	2020
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current oncology reports, 2004, Volume: 6, Issue:4 Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation	2004
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm	2000

Trials

6 trials available for risedronic acid and Cancer of Prostate

Article	Year
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010, Volume: 18, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Double-Blind	2010
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU international, 2010, Volume: 106, Issue:10 Topics: Aged; Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Epidemiologic	2010
Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. Prostate cancer and prostatic diseases, 2011, Volume: 14, Issue:3 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antineoplastic Age	2011
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com	2012
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Cons	2013
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:12 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Bone Density Conservation Agents; Etidroni	2007

Other Studies

4 other studies available for risedronic acid and Cancer of Prostate

Article	Year
A dramatic increase in bone mineral density, enhanced osteoblast activity and malignancy. QJM : monthly journal of the Association of Physicians, 2020, Apr-01, Volume: 113, Issue:4 Topics: Absorptiometry, Photon; Aged, 80 and over; Bone Density; Humans; Lumbar Vertebrae; Male; Osteoblasts	2020
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial	2013
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology, 2009, Volume: 73, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Resorption; Et	2009
[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2008, Volume: 99, Issue:1 Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fracture	2008